3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Renal Cell
132
Carcinoma, Transitional Cell
91
Carcinoma, Non-Small-Cell Lung
84
Urinary Bladder Neoplasms
81
Melanoma
75
Squamous Cell Carcinoma of Head and Neck
50
Prostatic Neoplasms
49
Colorectal Neoplasms
41
Ovarian Neoplasms
36
Stomach Neoplasms
35
Triple Negative Breast Neoplasms
33
Neoplasm Metastasis
32
Uterine Cervical Neoplasms
31
Neoplasms
28
Kidney Neoplasms
27
Breast Neoplasms
27
Parkinson Disease 4, Autosomal Dominant Lewy Body
26
Lung Neoplasms
26
Pancreatic Neoplasms
23
Carcinoma, Hepatocellular
23
Esophageal Neoplasms
21
Head and Neck Neoplasms
20
Endometrial Neoplasms
18
Small Cell Lung Carcinoma
16
Carcinoma, Merkel Cell
11
Mesothelioma
9
Cholangiocarcinoma
9
Ureteral Neoplasms
8
Sarcoma
8
Carcinoma, Ovarian Epithelial
8
Interventions
padeliporfin
5
Lycopene
3
pembrolizumab
2
darolutamide
2
Vitamin E
2
Tea
2
Selenium
2
Cholecalciferol
2
relatlimab
1
palladium-bacteriopheophorbide
1
olaparib
1
gedatolisib
1
enfortumab vedotin
1
Therapeutics
1
Sugars
1
Radiation Dose Hypofractionation
1
Pluvicto
1
Nivolumab
1
Mitomycin
1
Intraoperative Neurophysiological Monitoring
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
CP protocol
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Male Urogenital Diseases
×
pembrolizumab
×
Genitourinary
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled
NCT06353906
2025-12-08
PRIAM
The Netherlands Cancer Institute
Phase 2
Recruiting
27 enrolled